SUPPLEMENTARY INFORMATION CONTAINS A LIST OF THE RELEVANT
ABSTRACTS CITED IN THIS ARTICLE FROM THE EASL 2006, DDW 2006,
AASLD 2005 and 2006 MEETINGS.
1
Colombo M (Ed.; 2006) Abstracts of the 41st Annual Meeting of the European
Association for the Study of the Liver: 2006 April 26–30; Vienna. J Hepatol 44 (Suppl
2): S3–S278
Taribavirin
Abstract 75. Benhamou Y et al. (2006) The safety and efficacy of viramidine plus
pegylated interferon alfa-2a versus ribavirin plus pegylated interferon alfa-2b in therapynaive patients infected with HCV: phase III results. J Hepatol 44: S273
Telaprevir
Abstract 12. Reesink HW et al. (2006) Initial results of a 14-day study of the hepatitis C
virus inhibitor protease VX-950, in combination with peginterferon-alpha-2a. J Hepatol
44: S272
Abstract 12. Kieffer T et al. (2006) Wild-yype HCV NS3 protease re-emerges during
follow-up after 14 days of dosing with VX-950 in patients wtih genotype 1 HCV. J
Hepatol 44: S7
R1626
Abstract 731. Roberts S et al. (2006) Interim results of a multiple ascending dose study of
R126, a novel nucleoside analog targeting HCV polymerase in chronic HCV patients. J
Hepatol 44: S269
2
Blei AT (Ed.; 2006) Abstracts of the 57th annual meeting of the American
Association for the Study of Liver Diseases (57th AASLD): 2006 October 27–31;
Boston. Hepatology 44 (Suppl 1): S1–S258
Eltrombopag
Abstract LB3. McHutchison J et al. (2006) Eltrombopag, an oral platelet growth factor,
facilitates initiation of interferon therapy in subjects with HCV associated
thrombocytopenia: results from a phase II placebo controlled, double-blind, dose-ranging
study
Albumin interferon
Abstract 1136. Nelson D et al. (2006) Sustained virologic response rates with albumin
interferon alfa-2b in combination with ribavirin in non-responders to prior interferon
therapy: interim results from a phase II study. Hepatology 44 (Suppl 1): A611
Abstract 1141. Zeuzem S et al. (2006) Interim (week 12) phase IIb virological efficacy
and safety results of albumin interferon alpha-2b combined with ribavirin in genotype 1
chronic hepatitis C infection. J Hepatol 44: S270
Telaprevir
Abstract 92. Kieffer T et al. (2006) Combination of telaprevir (VX-950) and PEG IFN
alpha suppresses both wild-type virus and resistance variants in HCV genotype 1-infected
patients in a 14 day phase 1b study. Hepatology 44 (Suppl 1): A222
Abstract 927. Rodriguez-Torres M et al. (2006) Current status of subjects receiving peginterferon-alfa-2A (PEG-IF) and ribavirin (RBV) follow-on therapy after 28-day
treatment with the hepatitis C protease inhibitor teleaprevir (VX-950), PEG-IFN and
RBV. Hepatology 44 (Suppl 1): A532
Abstract 1142. Forestier N et al. (2006) Current status of subjects receiving peginterferon-alfa-2A (PEG-IFN) and ribavirin (RBV) after a 14-day study of the hepatitis C
protease inhibitor telaprevir (VX-950) with PEG-IFN. Hepatology 44 (Suppl 1): A614
Valopicitabine
Abstract 93. Lawitz E et al. (2006) Valopicitabine (NM283) plus PEG-interferon in
treatment-naive hepatitis C patients with HCV genotype 1 infection: HCV RNA
clearance during 24 weeks of treatment. Hepatology 44 (Suppl 1): A223
ITMN-191
Abstract 933. Tan H et al. (2006) In vitro synergistic antiviral activity of ITMN-191, an
orally active inhibitor of the hepatitis C virus (HCV) NS3/4A protease, in combination
with PEG-interferon alfa-2a. Hepatology 44 (Suppl 1): A534
CpG 10101
Abstract 96. Jacobson IM et al. (2006) Early viral response and on treatment response to
CpG 10101 (Actilon), in combination with pegylated interferon and/or ribavirin, in
chronic HCV genotype 1 infected patients with prior relapse response. Hepatology 44
(Suppl 1): A224
GI-5005
Abstract LB17. Everson GT et al. (2006) Interim results from a randomized, doubleblind, placebo-controlled phase 1b study in subjects with chronic HCV after treatment
with GI-5005, a yeast-based HCV immunotherapy targeting NS3 and core proteins.
Hepatology 44: A697
4
Blei AT (Ed.; 2005) Abstracts of the 56th annual meeting of the American
Association for the Study of Liver Diseases (56th AASLD): 2005 November 11–15; San
Francisco. Hepatology 42 (Suppl 1): S1–S257
Omega interferon
Abstract 1284. Gorbakov VV et al. (2005) HCV RNA results from a phase II,
randomized, open-label study of omega interferon (IFN) with or without ribavirin in IFNnaive genotype 1 chronic HCV patients. Hepatology 42: A705
Telaprevir
Abstract 737. Reesink HW et al. (2005) Final results of a phase 1B, multiple-dose study
of VX-950, a hepatitis C virus protease inhibitor. Hepatology 42: A234-235
SCH 503034
Abstract 94. Zeuzem S et al. (2005) Anti-viral activity of SCH 503034, a HCV protease
inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients
refractory to pegylated interferon (Peg-IFNA233
Abstract 201. Zeuzem S et al. (2005) Combination therapy with the HCV protease
inhibitor, SCH 503034, plus Peg-intron in hepatitis C genotype-1 Peg-intron nonresponders: phase 1B results. Hepatology 42: A276-A277
NIM811
Abstract 866. Lin K et al. (2005) NIM811 exhibits potent anti-HCV activity in vitro and
represents a novel approach for vial hepatitis C therapy. Hepatology A536
Valopicitabine
Abstract 4. Pockros P et al. (2006) Valopicitabine (NM283), alone or with peg-interferon,
compared to peg-interferon/ribavirin (pegIFN/RBV) retreatment in hepatitis C patients
with prior non-response to pegIFN/RBV: week 24 results. Gastro 130: A748
5
Digestive Disease Week, May 21–24, 2006, Los Angeles, CA. Gastroenterology 5
Telaprevir
Abstract 96. Lawitz EJ et al. (2006) 28 days of the hepatitis C protease inhibitor VX-950,
in combination with peg-interferon-alfa-2a and ribavirin, is well-tolerated and
demonstrates robust antiviral effects. Abstract 686f. DDW